RDUS

Radius Health, Inc. [RDUS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RDUS Stock Summary

Top 10 Correlated ETFs

RDUS

Top 10 Correlated Stocks

RDUS

In the News

RDUS Financial details

Company Rating
-
Market Cap
485.25M
Income
-25.97M
Revenue
2.96B
Book val./share
-
Cash/share
-
Dividend
0.56
Dividend %
2.06%
Employees
293
Optionable
No
Shortable
Yes
Earnings
09 Aug 2022
P/E
73.88
Forward P/E
-
PEG
-6.41
P/S
0.25
P/B
0.82
P/C
-
P/FCF
24.91
Quick Ratio
0.88
Current Ratio
1.93
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.92
EPS next Y
-
EPS next Q
-
EPS this Y
-115.31%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-20.46%
Revenue last 5Y
75.46%
Revenue Q/Q
-6.27%
EPS Q/Q
-30.43%
-
-
-
-
SMA20
71.65%
SMA50
129.68%
SMA100
52.4%
Inst Own
-
Inst Trans
-
ROA
1%
ROE
1%
ROC
0.02%
Gross Margin
10%
Oper. Margin
1%
Profit Margin
-
Payout
204%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
17.0-36.64
52W High
-19.25%
52W Low
+71%
RSI
79.82
Rel Volume
4.08
Avg Volume
213.81K
Volume
872.17K
Perf Week
-0.17%
Perf Month
110.2%
Perf Quarter
57.14%
Perf Half Y
54.63%
-
-
-
-
Beta
0.51647
-
-
Volatility
0.21%, 7.05%
Prev Close
0.28%
Price
29.07
Change
0.76%

RDUS Financial Performance

RDUS Dividend History

RDUS Frequently Asked Questions

What is Radius Health, Inc. stock symbol ?

Radius Health, Inc. is a US stock , located in Waltham of Massachusetts and trading under the symbol RDUS

What is Radius Health, Inc. stock quote today ?

Radius Health, Inc. stock price is $29.07 today.

Is Radius Health, Inc. stock public?

Yes, Radius Health, Inc. is a publicly traded company.

Something similar

Top by Market Cap
FB2A.DE
DHR-PB
NVD.DE
3V64.DE
JPM
Top Correlated ETFs
GLDI
INDF
TIGR.L
JEST.DE
BGLD
Top Correlated Stocks
BNKL
AAEV.L
AATG.L
TNRG
WBBW
Similar Market Cap
TETCU
MWY.L
GAU.TO
1808.HK
ZEF.TO

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 213.81K
  • Market Capitalization 485.25M
  • Employee 293
  • CEO Mr. Jesper Hoiland
  • Headquarters Waltham,MASSACHUSETTS,US
  • IPO Date 2014-06-06
  • Website https://radiuspharm.com

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.